HMG-I/HMG-Y Inhibitors
High Mobility Group I (HMG-I) and High Mobility Group Y (HMG-Y) are non-histone chromosomal proteins that play pivotal roles in the regulation of DNA-dependent processes such as transcription, replication, and DNA repair. These proteins are known for their ability to bind to AT-rich regions of DNA, thereby influencing the architecture of chromatin and facilitating the assembly of transcription complexes at gene promoters. Through these interactions, HMG-I/Y proteins act as architectural transcription factors, modulating the expression of genes involved in cell growth, differentiation, and response to external signals. The importance of HMG-I/Y in regulating gene expression is underscored by their involvement in several critical cellular pathways and their association with the development and progression of various types of cancer, where they are often overexpressed, leading to the dysregulation of gene expression profiles critical for cellular proliferation and survival.
The inhibition of HMG-I/Y function provides a strategy to modulate aberrant gene expression patterns associated with pathological states, including cancer. Inhibition can occur through various mechanisms, including the direct interference with the DNA-binding activity of HMG-I/Y proteins, altering their post-translational modifications, or affecting their expression levels. For example, modifying the phosphorylation status of HMG-I/Y proteins can influence their interaction with DNA and other transcriptional regulators, thereby affecting their ability to modulate gene expression. Similarly, strategies that reduce the expression of HMG-I/Y proteins can lead to changes in chromatin structure and gene expression, reversing the aberrant cellular phenotypes associated with their overexpression. These mechanisms of inhibition highlight the complex regulation of HMG-I/Y activity and the ability of targeting these proteins to modulate gene expression in diseases characterized by their dysregulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D inhibits HMG-I/HMG-Y by intercalating into DNA and preventing transcription. This direct inhibition disrupts the binding of HMG-I/HMG-Y to the DNA, hindering its regulatory role in gene expression. The interference with DNA binding showcases Actinomycin D's potential as a precise modulator of HMG-I/HMG-Y activity, providing insights into the specific mechanisms underlying transcriptional regulation. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $58.00 $186.00 $94.00 | 21 | |
Camptothecin acts as an indirect inhibitor of HMG-I/HMG-Y by targeting DNA topoisomerase I. This interaction leads to the formation of stable DNA-topoisomerase I-Camptothecin complexes, inhibiting the relaxation of supercoiled DNA. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $55.00 | 6 | |
Mithramycin inhibits HMG-I/HMG-Y by binding to the DNA minor groove, preventing the interaction with transcription factors. This direct inhibition disrupts the regulatory role of HMG-I/HMG-Y in gene expression. Mithramycin's mechanism showcases its potential as a specific modulator of HMG-I/HMG-Y activity, providing insights into the structural aspects of DNA-protein interactions and their implications in transcriptional regulation. | ||||||
Ellipticine | 519-23-3 | sc-200878 sc-200878A | 10 mg 50 mg | $145.00 $569.00 | 4 | |
Ellipticine acts as an indirect inhibitor of HMG-I/HMG-Y by intercalating into DNA, affecting its structure and dynamics. This interaction influences DNA-protein binding, hindering the regulatory role of HMG-I/HMG-Y in transcription. The indirect modulation by Ellipticine highlights its potential in altering DNA conformation and its impact on HMG-I/HMG-Y function, providing insights into the dynamic aspects of DNA-protein interactions in gene expression regulation. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $37.00 $152.00 | 11 | |
Fluorouracil acts as an indirect inhibitor of HMG-I/HMG-Y by disrupting nucleotide metabolism. Incorporated into RNA and DNA, Fluorouracil interferes with normal cellular processes, potentially affecting the binding and function of HMG-I/HMG-Y. This indirect modulation illustrates the impact of nucleotide analogs on HMG-I/HMG-Y activity, providing insights into the broader cellular consequences of disrupting nucleotide metabolism on gene expression regulation. | ||||||
Mitoxantrone | 65271-80-9 | sc-207888 | 100 mg | $285.00 | 8 | |
Mitoxantrone inhibits HMG-I/HMG-Y by intercalating into DNA and inducing topoisomerase II-mediated DNA cleavage. This direct inhibition disrupts DNA structure and prevents HMG-I/HMG-Y binding, hindering its regulatory role in gene expression. Mitoxantrone's mechanism showcases its potential as a targeted modulator of HMG-I/HMG-Y activity, providing insights into the interplay between DNA topology, topoisomerases, and the regulation of gene expression. | ||||||
Aclacinomycin A | 57576-44-0 | sc-200160 | 5 mg | $132.00 | 10 | |
Aclacinomycin A acts as an indirect inhibitor of HMG-I/HMG-Y by intercalating into DNA and inhibiting topoisomerase II. This interference with DNA structure and topoisomerase II activity disrupts the regulatory role of HMG-I/HMG-Y in gene expression. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Etoposide acts as an indirect inhibitor of HMG-I/HMG-Y by inhibiting topoisomerase II, leading to DNA damage. This indirect modulation disrupts DNA structure and potentially affects the binding and function of HMG-I/HMG-Y. Etoposide's mechanism highlights the impact of topoisomerase II inhibitors on HMG-I/HMG-Y activity, providing insights into the broader consequences of DNA damage on gene expression regulation. | ||||||
Ellagic Acid, Dihydrate | 476-66-4 | sc-202598 sc-202598A sc-202598B sc-202598C | 500 mg 5 g 25 g 100 g | $58.00 $95.00 $245.00 $727.00 | 8 | |
Ellagic Acid acts as an indirect inhibitor of HMG-I/HMG-Y by modulating redox signaling and inhibiting NF-κB. This indirect modulation affects the binding and function of HMG-I/HMG-Y, potentially through the NF-κB pathway. Ellagic Acid's mechanism highlights the crosstalk between redox signaling, transcription factors, and the regulation of HMG-I/HMG-Y activity, providing insights into the intricate network of cellular processes influencing gene expression. | ||||||